+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Myocardial Ischemia (Cardiovascular) - Drugs In Development, 2021

  • ID: 5359592
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 96 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Angionetics Inc
  • BioCardia Inc
  • Caladrius Biosciences Inc
  • CohBar Inc
  • NervGen Pharma Corp
  • Omniox Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Ischemia (Cardiovascular) - Drugs In Development, 2021, provides an overview of the Myocardial Ischemia (Cardiovascular) pipeline landscape.

Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm and severe illnesses. The factors that may increase the risk of developing myocardial ischemia include tobacco, diabetes, high blood pressure, high blood cholesterol or triglyceride levels, lack of physical activity, obesity and family history.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Myocardial Ischemia (Cardiovascular) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Myocardial Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 1, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Myocardial Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Ischemia (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Ischemia (Cardiovascular)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Ischemia (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Angionetics Inc
  • BioCardia Inc
  • Caladrius Biosciences Inc
  • CohBar Inc
  • NervGen Pharma Corp
  • Omniox Inc
Introduction
  • Report Coverage
Myocardial Ischemia - Overview

Myocardial Ischemia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Myocardial Ischemia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Myocardial Ischemia - Companies Involved in Therapeutics Development
  • Angionetics Inc
  • AstraZeneca Plc
  • BioCardia Inc
  • Cadrock Pty Ltd
  • Caladrius Biosciences Inc
  • Cellmid Ltd
  • Chrysalis BioTherapeutics Inc
  • CohBar Inc
  • Eight Plus One Pharmaceutical Co Ltd
  • Everon Biosciences Inc
  • Guangzhou Magpie Pharmaceutical Co Ltd
  • Lixte Biotechnology Holdings Inc
  • NervGen Pharma Corp
  • NoNO Inc
  • Omniox Inc
  • Q BioMed Inc
  • Symvivo Inc
  • Vasade Biosciences Inc
Myocardial Ischemia - Drug Profiles

alferminogene tadenovec - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
AZD-8601 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
azithromycin + doxycycline + rifabutin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
BJY-802 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CardiAMP - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CLBS-14 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CMK-103 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
DT-010 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Gene Therapy for Myocardial Ischemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Humanin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
LB-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
MAN-04 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
NVG-291R - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
OMX-4.80P - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
PMC-6 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
rusalatide acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
sirolimus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
XG-19 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Myocardial Ischemia - Dormant Projects

Myocardial Ischemia - Discontinued Products

Myocardial Ischemia - Product Development Milestones

Featured News & Press Releases
  • Jun 22, 2021: BioCardia to present CardiAMP cell therapy clinical trial data at European Society of Cardiology Heart Failure 2021
  • Feb 20, 2019: Phase 1 data published in Nature Communications show potential of mRNA encoding VEGF-A as a regenerative therapeutic
  • Jan 09, 2017: Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart Disease
  • Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease
  • May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities
  • Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
  • Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City
  • Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology
  • Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention
  • Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings
  • May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy
  • Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease
  • Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy
  • Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study
  • Feb 28, 2012: Baxter Initiates Phase III Adult Stem Cell Clinical Trial For Chronic Cardiac Condition
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development for Myocardial Ischemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Myocardial Ischemia - Pipeline by Angionetics Inc, 2021
  • Myocardial Ischemia - Pipeline by AstraZeneca Plc, 2021
  • Myocardial Ischemia - Pipeline by BioCardia Inc, 2021
  • Myocardial Ischemia - Pipeline by Cadrock Pty Ltd, 2021
  • Myocardial Ischemia - Pipeline by Caladrius Biosciences Inc, 2021
  • Myocardial Ischemia - Pipeline by Cellmid Ltd, 2021
  • Myocardial Ischemia - Pipeline by Chrysalis BioTherapeutics Inc, 2021
  • Myocardial Ischemia - Pipeline by CohBar Inc, 2021
  • Myocardial Ischemia - Pipeline by Eight Plus One Pharmaceutical Co Ltd, 2021
  • Myocardial Ischemia - Pipeline by Everon Biosciences Inc, 2021
  • Myocardial Ischemia - Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, 2021
  • Myocardial Ischemia - Pipeline by Lixte Biotechnology Holdings Inc, 2021
  • Myocardial Ischemia - Pipeline by NervGen Pharma Corp, 2021
  • Myocardial Ischemia - Pipeline by NoNO Inc, 2021
  • Myocardial Ischemia - Pipeline by Omniox Inc, 2021
  • Myocardial Ischemia - Pipeline by Q BioMed Inc, 2021
  • Myocardial Ischemia - Pipeline by Symvivo Inc, 2021
  • Myocardial Ischemia - Pipeline by Vasade Biosciences Inc, 2021
  • Myocardial Ischemia - Dormant Projects, 2021
  • Myocardial Ischemia - Discontinued Products, 2021
List of Figures
  • Number of Products under Development for Myocardial Ischemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • Angionetics Inc
  • AstraZeneca Plc
  • BioCardia Inc
  • Cadrock Pty Ltd
  • Caladrius Biosciences Inc
  • Cellmid Ltd
  • Chrysalis BioTherapeutics Inc
  • CohBar Inc
  • Eight Plus One Pharmaceutical Co Ltd
  • Everon Biosciences Inc
  • Guangzhou Magpie Pharmaceutical Co Ltd
  • Lixte Biotechnology Holdings Inc
  • NervGen Pharma Corp
  • NoNO Inc
  • Omniox Inc
  • Q BioMed Inc
  • Symvivo Inc
  • Vasade Biosciences Inc
Note: Product cover images may vary from those shown
Adroll
adroll